Andrew Norris
Company: BCN Biosciences
Job title: Co-Founder & Chief Scientific Officer
Seminars:
Panel : Debating Optimal PK/PD Profiles to Carve Out the Optimal Inhibitor for Targeting RAS 1:45 pm
day: Day Two Track A PM
Exploring Mechanisms of Action & Navigating Agent Synergy in the Pre-clinic to Improve the Efficacy of Combination Therapies 2:30 pm
Current pre-clinical exploration in combination strategies for targeting RAS-driven tumors is underscored by selecting synergistic agents with complementary mechanisms to overcome acquired resistance. Amidst the emergence of diverse modalities, a deeper understanding of the interplay between targeted proteins and up/downstream pathways is crucial, alongside toxicity risks. This workshop will shed light on promising combinations in…Read more
day: Workshop E